SCHEMBL4644479

SCHEMBL4644479

CC(C)(C)OC(=O)c1c(N)cccc1B(O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.43
ALDH1A1 P00352 7/20 0.38
HPGD P15428 4/20 0.38
KDM4E B2RXH2 3/20 0.38
GLA P06280 3/20 0.38
GAA P10253 3/20 0.38
MAPT P10636 2/20 0.38
HIF1A Q16665 2/20 0.38
THRB P10828 1/20 0.38
SLC7A5 Q01650 1/20 0.37
HSD17B10 Q99714 4/20 0.36
CFTR P13569 1/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2730411 0.88 GRM6 (0.49) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL2718238 0.81 CA12 (0.48) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL10982569 0.80 GRM6 (0.43) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL6830109 0.80 POLB (0.45) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL976497 0.79 MMP2 (0.47) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL3586373 0.79 CA12 (0.38) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL27651123 0.78 GRM6 (0.42) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL31461653 0.77 THRB (0.43) ALDH1A1KDM4EMAPTTHRBHSD17B10
SCHEMBL31020766 0.76 GRM6 (0.41) GRM6ALDH1A1HPGDKDM4EGLA
SCHEMBL27770533 0.76 GRM6 (0.41) GRM6ALDH1A1HPGDKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288398-B2 Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones MERCK SERONO SA (CH) 2012-10-16 US disclosed
US-20120238575-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES MERCK SERONO SA (CH) 2012-09-20 US disclosed
US-20080287474-A1 Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones LABORATOIRES SERONO SA (CH) 2008-11-20 US disclosed
EP-1963321-A2 DIBENZONAPHTHYRIDINE DERIVATIVES AND METHODS OF USE THEREOF Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
EP-1957469-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES Laboratoires Serono SA (CH) 2008-08-20 EP disclosed
US-7388016-B2 Dibenzonaphthyridine derivatives and methods of use thereof WYETH (US) 2008-06-17 US disclosed
WO-2007070319-A2 DIBENZONAPHTHYRIDINE DERIVATIVES AND METHODS OF USE THEREOF WYETH (US) 2007-06-21 WO disclosed
US-20070135429-A1 Dibenzonaphthyridine derivatives and methods of use thereof WYETH (US) 2007-06-14 US disclosed
WO-2007065940-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES LABORATOIRES SERONO S.A. (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287474-A1 Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones TYMP, DHFR, DPYD GRM6 3883/4885ALDH1A1 120/4885HPGD 353/4885
US-20120238575-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES TYMP, DHFR, DPYD GRM6 3883/4885ALDH1A1 120/4885HPGD 353/4885
US-20070135429-A1 Dibenzonaphthyridine derivatives and methods of use thereof FANCD2, DDT, BRCA1 GRM6 4658/4885ALDH1A1 946/4885HPGD 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.